Actualités Corvus Pharmaceuticals Inc - CRVS | Actions NASDAQ

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

Findings may provide a treatment that enables discontinuation of HIV antiretroviral therapy by preventing...

Amended Statement of Ownership (sc 13g/a)

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A ...

Statement of Ownership (sc 13g)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of...

Amended Statement of Ownership (sc 13g/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Results in patients with refractory T cell lymphoma demonstrated CPI-818’s anti-tumor activity and effects on T...

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

BURLINGAME, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company...

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

BURLINGAME, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- James T. Rosenbaum, MD, Senior Vice President of...

Amended Current Report Filing (8-k/a)

0001626971 true 0001626971 2022-06-15 2022-06-15 iso4217:USD xbrli:shares...

Current Report Filing (8-k)

0001626971 False 0001626971 2022-11-03 2022-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATESSECURITIES AND EXCHANGE...

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

Data From CPI-818 T Cell Lymphoma Study Accepted for Presentation at the 64th ASH Annual Meeting and...

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

BURLINGAME, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a...

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

BURLINGAME, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Corvus Pharmaceuticals Inc (CRVS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CRVS Actualités

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

Amended Statement of Ownership (sc 13g/a)

Statement of Ownership (sc 13g)

Amended Statement of Ownership (sc 13g/a)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

Amended Current Report Filing (8-k/a)

Current Report Filing (8-k)

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Corvus Pharmaceuticals Inc (CRVS) Actualités

Corvus Pharmaceuticals Inc (CRVS)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

CRVS Actualités

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

Amended Statement of Ownership (sc 13g/a)

Statement of Ownership (sc 13g)

Amended Statement of Ownership (sc 13g/a)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

Amended Current Report Filing (8-k/a)

Current Report Filing (8-k)

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application